Cargando…

Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine

The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebeau, Grégorie, Lagrave, Alisé, Ogire, Eva, Grondin, Lauriane, Seriacaroupin, Soundary, Moutoussamy, Cédric, Mavingui, Patrick, Hoarau, Jean-Jacques, Roche, Marjolaine, Krejbich-Trotot, Pascale, Desprès, Philippe, Viranaicken, Wildriss
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471935/
https://www.ncbi.nlm.nih.gov/pubmed/34579183
http://dx.doi.org/10.3390/vaccines9090946
_version_ 1784574595504799744
author Lebeau, Grégorie
Lagrave, Alisé
Ogire, Eva
Grondin, Lauriane
Seriacaroupin, Soundary
Moutoussamy, Cédric
Mavingui, Patrick
Hoarau, Jean-Jacques
Roche, Marjolaine
Krejbich-Trotot, Pascale
Desprès, Philippe
Viranaicken, Wildriss
author_facet Lebeau, Grégorie
Lagrave, Alisé
Ogire, Eva
Grondin, Lauriane
Seriacaroupin, Soundary
Moutoussamy, Cédric
Mavingui, Patrick
Hoarau, Jean-Jacques
Roche, Marjolaine
Krejbich-Trotot, Pascale
Desprès, Philippe
Viranaicken, Wildriss
author_sort Lebeau, Grégorie
collection PubMed
description The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent the risk of hemorrhage. Dengue is caused by one of four genetically related but antigenically distinct serotypes DENV-1–DENV-4. The growing burden of the four DENV serotypes has intensified both basic and applied research to better understand dengue physiopathology. Research has shown that the secreted soluble hexameric form of DENV nonstructural protein-1 (sNS1) plays a significant role in the pathogenesis of severe dengue. Here, we provide an overview of the current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease. We discuss the potential use of sNS1 in future vaccine development and its potential to improve dengue vaccine efficiency, particularly against severe dengue illness.
format Online
Article
Text
id pubmed-8471935
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84719352021-09-28 Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine Lebeau, Grégorie Lagrave, Alisé Ogire, Eva Grondin, Lauriane Seriacaroupin, Soundary Moutoussamy, Cédric Mavingui, Patrick Hoarau, Jean-Jacques Roche, Marjolaine Krejbich-Trotot, Pascale Desprès, Philippe Viranaicken, Wildriss Vaccines (Basel) Review The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent the risk of hemorrhage. Dengue is caused by one of four genetically related but antigenically distinct serotypes DENV-1–DENV-4. The growing burden of the four DENV serotypes has intensified both basic and applied research to better understand dengue physiopathology. Research has shown that the secreted soluble hexameric form of DENV nonstructural protein-1 (sNS1) plays a significant role in the pathogenesis of severe dengue. Here, we provide an overview of the current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease. We discuss the potential use of sNS1 in future vaccine development and its potential to improve dengue vaccine efficiency, particularly against severe dengue illness. MDPI 2021-08-25 /pmc/articles/PMC8471935/ /pubmed/34579183 http://dx.doi.org/10.3390/vaccines9090946 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lebeau, Grégorie
Lagrave, Alisé
Ogire, Eva
Grondin, Lauriane
Seriacaroupin, Soundary
Moutoussamy, Cédric
Mavingui, Patrick
Hoarau, Jean-Jacques
Roche, Marjolaine
Krejbich-Trotot, Pascale
Desprès, Philippe
Viranaicken, Wildriss
Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine
title Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine
title_full Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine
title_fullStr Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine
title_full_unstemmed Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine
title_short Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine
title_sort viral toxin ns1 implication in dengue pathogenesis making it a pivotal target in development of efficient vaccine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471935/
https://www.ncbi.nlm.nih.gov/pubmed/34579183
http://dx.doi.org/10.3390/vaccines9090946
work_keys_str_mv AT lebeaugregorie viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT lagravealise viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT ogireeva viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT grondinlauriane viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT seriacaroupinsoundary viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT moutoussamycedric viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT mavinguipatrick viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT hoaraujeanjacques viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT rochemarjolaine viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT krejbichtrototpascale viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT despresphilippe viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine
AT viranaickenwildriss viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine